Biota Pharmaceuticals

The Company has four product candidates in development that address viral infections that have limited therapeutic options.
We are currently enrolling patients for the Phase 2b SPIRITUS trial for vapendavir, a potent, broad spectrum capsid inhibitor of enteroviruses, for the treatment of human rhinovirus (HRV) infected patients with moderate-to-severe asthma. Our second Phase 2 clinical product candidate is BTA074 (AP611074), a novel topical treatment for genital warts caused by HPV types 6 & 11. We also are developing BTA-C585, an oral fusion inhibitor in development for the treatment of respiratory syncytial virus infections. We anticipate beginning a Phase 1 clinical trial with BTA-C585 in Q3 2105. Laninamivir octanoate, a one-time, inhaled neuraminidase for the treatment of influenza A and B infections has completed a global Phase 2 trial. 
In addition to our research and development activities, we receive royalty revenue from two approved neuraminidase inhibitors: zanamivir, marketed worldwide as Relenza® by GlaxoSmithKline; and LANI, marketed in Japan as Inavir® by Daiichi-Sankyo.

Type
Public
HQ
Alpharetta, US
Founded
1984
Size (employees)
19 (est)
Biota Pharmaceuticals was founded in 1984 and is headquartered in Alpharetta, US

Biota Pharmaceuticals Office Locations

Biota Pharmaceuticals has office in Alpharetta
Alpharetta, US

Biota Pharmaceuticals Metrics

Biota Pharmaceuticals Financials

Biota Pharmaceuticals's revenue is $9.3 m in FY, 2016 which is a 62.2% decrease from the previous period.
FY, 2014FY, 2015FY, 2016

Revenue

$68.7 m$24.6 m$9.3 m

Revenue growth, %

(64.2%)(62.2%)

Gross profit

$17.6 m$21 m

Operating expense total

$80.2 m$44.1 m$34.5 m

EBIT

($11.5 m)($19.5 m)($25.2 m)

Net Income

($11 m)($19.1 m)($25.4 m)

Operating cash flow

$13.4 m($29.1 m)$5 m

Biota Pharmaceuticals Company Life

You may also be interested in